<DOC>
	<DOCNO>NCT01710358</DOCNO>
	<brief_summary>The purpose study determine whether baricitinib superior placebo treatment participant moderately severely active Rheumatoid Arthritis ( RA ) inadequate response methotrexate ( MTX ) treatment .</brief_summary>
	<brief_title>A Study Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Have diagnosis adultonset Rheumatoid Arthritis ( RA ) define American College Rheumatology/ European League Against Rheumatism ( ACR/EULAR ) 2010 Criteria Classification RA Have moderately severely active RA define presence least 6/68 tender joint least 6/66 swollen joint Have Creactive protein ( CRP ) highsensitivity Creactive protein ( hsCRP ) measurement ≥6 milligram per Liter ( mg/L ) Have regular use methotrexate ( MTX ) least 12 week prior study entry dose consider acceptable adequately assess clinical response . Have least 1 joint erosion hand , wrist , foot joint base radiographic interpretation central reader rheumatoid factor anticyclic citrullinated peptide ( antiCCP ) antibody positive ; least 3 joint erosion hand , wrist , foot joint base radiographic interpretation central reader regardless rheumatoid factor antiCCP antibody status Are currently receive corticosteroid dos &gt; 10 mg prednisone per day ( equivalent ) receive unstable dose regimen corticosteroid within 2 week study entry within 6 week plan randomization Have start treatment nonsteroidal antiinflammatory drug ( NSAIDs ) receive unstable dose regimen NSAIDs within 2 week study entry within 6 week plan randomization Are currently receive concomitant treatment MTX , hydroxychloroquine , sulfasalazine combination 3 conventional diseasemodifying antirheumatic drug ( cDMARDs ) Are currently receive receive cDMARDs ( eg , gold salt , cyclosporine , azathioprine , immunosuppressive ) MTX , hydroxychloroquine ( 400 mg/day ) , sulfasalazine ( 3000 mg/day ) within 4 week prior study entry Have receive leflunomide 12 week prior study entry start new physiotherapy treatment RA 2 week prior study entry Have ever receive biologic diseasemodifying antirheumatic drug ( DMARD ) Have receive interferon therapy within 4 week prior study entry anticipate require interferon therapy study Have receive parenteral corticosteroid administer intramuscular intravenous injection within 2 week prior study entry within 6 week prior plan randomization anticipate require parenteral injection corticosteroid study Have 3 joint injected intraarticular corticosteroid hyaluronic acid within 2 week prior study entry within 6 week prior plan randomization Have condition contraindication adalimumab would preclude participant participate protocol Have active fibromyalgia would make difficult appropriately assess RA activity purpose study Have diagnosis systemic inflammatory condition RA , limit , juvenile chronic arthritis , spondyloarthropathy , Crohn 's disease , ulcerative colitis , psoriatic arthritis , active vasculitis gout ( participant secondary Sjögren 's syndrome exclude ) Have diagnosis Felty 's syndrome Have major surgery within 8 week prior study entry require major surgery study , opinion investigator consultation Lilly designee , would pose unacceptable risk participant Have experience follow within 12 week study entry : myocardial infarction , unstable ischemic heart disease , stroke , New York Heart Association Stage IV heart failure Have history presence cardiovascular , respiratory , hepatic , gastrointestinal , endocrine , hematological , neurological , neuropsychiatric disorder serious and/or unstable illness , opinion investigator , could constitute risk take investigational product could interfere interpretation data Are largely wholly incapacitated permit little selfcare , bedridden confine wheelchair history , lymphoproliferative disease ; sign symptom suggestive possible lymphoproliferative disease , include lymphadenopathy splenomegaly ; active primary recurrent malignant disease ; remission clinically significant malignancy &lt; 5 year Have expose live vaccine within 12 week prior plan randomization expect need/receive live vaccine course study ( exception herpes zoster vaccination ) Have current recent clinically serious viral , bacterial , fungal , parasitic infection Have symptomatic herpes zoster infection within 12 week prior study entry Have history disseminated/complicated herpes zoster ( eg , multidermatomal involvement , ophthalmic zoster , central nervous system involvement , postherpetic neuralgia ) Are immunocompromised , opinion investigator , unacceptable risk participate study Have history active hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) Have screen laboratory test value , include thyroidstimulating hormone ( TSH ) , outside reference range population investigative site , opinion investigator , pose unacceptable risk participant 's participation study Have screen electrocardiogram ( ECG ) abnormality , opinion investigator sponsor , clinically significant indicate unacceptable risk participant 's participation study Have symptomatic herpes simplex time study enrollment Have evidence active latent tuberculosis ( TB )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>